New and emerging combination therapies for esophageal cancer

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 133-146

  Wiedmann, Marcus W ^a,b   Mössner, Joachim ^b  

^a St Mary's Hospital   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Chemoradiation; Chemotherapy; Molecular targeted therapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IFOSFAMIDE; IRINOTECAN; LAPATINIB; MITOMYCIN; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RAMUCIRUMAB; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMORADIOTHERAPY; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS SURGERY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOKALEMIA; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

EID: 84879705437     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S32199     Document Type: Review

References (112)

1. Wittekind C, Meyer HJ. Ösophagus einschließlich ösophagogastraler Übergang [Esophagus including esophagogastric junction]. In: TNM-Klassifkation Maligner Tumoren 2010, 7th ed. Leipzig, Germany: Springer-Verlag. 2010;63-68.
2. Mawhinney MR, Glasgow RE. Current treatment options for the management of esophageal cancer. Cancer Manag Res. 2012;4:367-377.
3. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neo-adjuvant chemotherapy or chemoradiotherapy for resectable esopha-geal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7): 681-692.
4. Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-FU versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68-74.
5. Cunningham D, Allum WH, Stenning S P, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11-20.
6. Ychou M, Boige V, Pignon J P, et al. Perioperative chemotherapy compared with surgery alone for resectable gastresophageal adenocarci-noma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715-1721.
7. Thuss-Patience PC, Hofheinz RD, Arnold D, et al. Perioperative chemotherapy with docetaxel, cisplatin, and capecitabine (DCX) in gas-troesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Ann Oncol. 2012;23(11):2827-2834.
8. Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-FU (DCF) for locally advanced esophageal and gastric adenocarci-noma: a multicenter phase II trial. Ann Oncol. 2012;23(6): 1512-1517.
9. Idelevich E, Kashtan H, Klein Y, et al. Prospective phase II study of neoadjuvant therapy with cisplatin, 5-FU, and bevacizumab for locally advanced resectable esophageal cancer. Onkologie. 2012;35(7-8): 427-431.
10. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10): 725-730.
11. Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327-2333.
12. Kofoed SC, Muhic A, Baeksgaard L, et al. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastroesophageal junction. Scand J Surg. 2012;101(1):26-31.
13. Leichman L P, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fuoroura-cil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol. 2011;29(34): 4555-4560.
14. Ilson DH, Minsky BD, Ku G Y, et al. Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer. 2012;118(11):2820-2827.
15. Pasini F, de Manzoni G, Zanoni A, et al. Neoadjuvant therapy with weekly docetaxel and cisplatin, 5-FU continuous infusion, and concurrent radiotherapy in patients with locally advanced esophageal cancer produced a high percentage of long-lasting pathological complete response: a phase 2 study. Cancer. 2013;119(5):939-945.
16. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084.
17. Jin HL, Zhu H, Ling TS, Zhang HJ, Shi RH. Neoadjuvant chemoradio-therapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol. 2009;15(47):5983-5991.
18. Nygaard K, Hagen S, Hansen HS, et al. Preoperative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of preoperative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16(6):1104-1109.
19. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41(4): 391-393.
20. Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73(7): 1779-1784.
21. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462-467.
22. Bosset JF, Gignoux M, Triboulet J P, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161-167.
23. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305-313.
24. Lee JL, Park SI, Kim SB, et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15(6):947-954.
25. Burmeister BH, Smithers BM, Gebski V, et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the esophagus: a randomized-controlled phase III trial. Lancet Oncol. 2005;6(9):659-668.
26. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fuorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-1092.
27. An FS, Huang JQ, Xie YT, Chen SH, Rong TH. A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma. Zhonghua Zhong Liu Za Zhi. 2003;25(4): 376-379. Chinese. [with English abstract].
28. Natsugoe S, Okumura H, Matsumoto M, et al. Randomized-controlled study on preoperative chemoradiotherapy followed by surgery versus surgery alone for esophageal squamous cell cancer in a single institution. Dis Esophagus. 2006;19(6):468-472.
29. Lv J, Cao X F, Zhu B, Ji L, Tao L, Wang DD. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010;16(13):1649-1654.
30. Mariette C, Seitz JF, Maillard E, et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized-controlled trial FFCD 9901. J Clin Oncol. 2010;28(Suppl 15):4005.
31. Bendell JC, Meluch A, Peyton J, et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol. 2012;10(7):430-437.
32. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623-1627.
33. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310-2317.
34. Bedenne L, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
35. Teoh AY, Chiu PW, Yeung WK, Liu SY, Wong SK, Ng EK, et al. Long-term survival outcomes after defnitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: results from a randomized-controlled trial. Ann Oncol. 2013;24(1): 165-171.
36. Conroy T, Galais M P, Raoul JL, et al. Phase Ill randomized trial of defnitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fuorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. J Clin Oncol. 2012;30.
37. Crosby T, Hurt C, Falk S, et al. SCOPE 1:A phase 11/111 trial of chemoradiotherapy in esophageal cancer plus or minus cetuximab. J Clin Oncol. 2012;30.
38. Shim HJ, Kim DE, Hwang JE, et al. A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced esophageal cancer. Cancer Chemother Pharmacol. 2012;70(5): 683-690.
39. Kranzfelder M, Schuster T, Geinitz H, Friess H, Büchler P. Meta-analysis of neoadjuvant treatment modalities and defnitive nonsurgical therapy for esophageal squamous cell cancer. Br J Surg. 2011;98(6):768-783.
40. Yoon MS, Nam TK, Lee JS, et al. VEGF as a predictor for response to defnitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci. 2011;26(4):513-520.
41. Bleiberg H, Conroy T, Paillot B, et al. Randomized phase II study of cisplatin and 5-FU (5-FU) versus cisplatin alone in advanced squamous cell esophageal cancer. Eur J Cancer. 1997;33(8):1216-1220.
42. Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fuorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28(9):1547-1553.
43. Lee J, Im YH, Cho EY, et al. A phase II study of capecitabine and cisplatin (XP) as frst-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2008;62(1):77-84.
44. Mauer AM, Kraut EH, Krauss SA, et al. Phase II trial of oxaliplatin, leucovorin, and fuorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol. 2005;16(8):1320-1325.
45. van Meerten E, Eskens FA, van Gameren EC, et al. First-line treatment with oxaliplatin and capecitabine in patients with advanced or meta-static esophageal cancer: a phase II study. Br J Cancer. 2007;96(9): 1348-1352.
46. Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecit-abine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17(1): 29-34.
47. Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008; 26(9):1435-1442.
48. Zhang X, Shen L, Li J, Li Y, Li J, Jin M. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol. 2008;31(1):29-33.
49. llson DH, Ajani J, Shalla K, et al. Phase II trial of paclitaxel, fuorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826-1834.
50. llson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophagea l cancer. J Clin Oncol. 1999;17: 3270-3275.
51. Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002;13:721-729.
52. Yun T, Han JY, Lee JS, et al. Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma. BMC Cancer. 2011;11:385.
53. Giordano K F, Jatoi A, Stella PJ, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroe-sophageal junction: a Phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17(4):652-656.
54. Lorenzen S, Duyster J, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic esophageal cancer: fnal results of a phase II trial. Br J Cancer. 2005;92(12): 2129-2133.
55. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1): 36-46.
56. Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fuorou-racil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol. 2005;23(24):5660-5667.
57. Lorenzen S, Hentrich M, Haberl C, et al. Split-dose docetaxel, cisplatin, and leucovorin/fuorouracil as frst-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol. 2007;18(10):1673-1679.
58. Evans D, Miner T, Iannitti D, et al. Docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer: a phase II study. Cancer Invest. 2007;25(6):445-448.
59. Tebbutt NC, Cummins MM, Sourjina T, et al. Randomized, noncom-parative phase II study of weekly docetaxel with cisplatin and 5-FU or with capecitabine in esophagogastric cancer: the AGITG ATTAX trial. Br J Cancer. 2010;102(3):475-481.
60. Huang J, Zhou Y, Zhang H, et al. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2013;30:343.
61. Itakura Y, Sasano H, Shiga C, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic fndings and DNA amplification. Cancer. 1994;74(3):795-804.
62. Kitagawa Y, Ueda M, Ando N, et al. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 1996;2(5):909-914.
63. Gibault L, Metges J P, Conan-Charlet V, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced esophageal squamous cell cancer. Br J Cancer. 2005;93(1):107-115.
64. Wilkinson N W, Black JD, Roukhadze E, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esopha-geal adenocarcinoma. J Gastrointest Surg. 2004;8(4):448-453.
65. Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101(8):1261-1268.
66. Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid, and 5-FU as frst-line treatment in advanced gastroesopha-geal cancer: a prospective multicenter biomarker-oriented phase II study. Ann Oncol. 2011;22(6):1358-1366.
67. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510-517.
68. Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/ leucovorin/5-FU in frst-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer. 2010;102(3):500-505.
69. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-FU versus cisplatin-5-FU alone in frst-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol. 2009;20(10):1667-1673.
70. Okines A F, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-fnding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J Clin Oncol. 2010;28(25):3945-3950.
71. Waddell TS, Chau I, Barbachano Y, et al. A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3). J Clin Oncol. 2012;30.
72. Wainberg ZA, Lin LS, DiCarlo B, et al. Phase II trial of modifed FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the esophagus and gastroesophageal junction. Br J Cancer. 2011;105(6):760-765.
73. al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer. 1993;54(2):213-219.
74. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19(5):554-568.
75. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastroesophageal junction cancer (ToGA): a Phase 3, open-label, randomized-controlled trial. Lancet. 2010;376(9742):687-697.
76. Galsky MD, Vo n Hoff DD, Neubauer M, et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplifed solid tumors. Invest New Drugs. 2012;30(2):695-701.
77. Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S. Vascular endothe-lial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer. 1997;79(2):206-213.
78. Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res. 1998;4(9):2195-2200.
79. Kleespies A, Guba M, Jauch K W, Bruns CJ, et al. Vascular endothe-lial growth factor in esophageal cancer. J Surg Oncol. 2004;87(2): 95-104.
80. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res. 2000;6(3):1161-1168.
81. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201-5206.
82. El-Rayes B F, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2009;21(10):1999-2004.
83. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: A randomized, double-blind, placebo controlled, phase Ill study of frst-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol. 2010;28:18s.
84. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29(6):1449-1458.
85. Sun W, Powell M, O'Dwyer PJ, Catalano P, Ansari RH, Benson AB 3rd. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010; 28(18):2947-2951.
86. Ku GY, Ilson DH, Schwartz LH, et al. Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer. Cancer Chemother Pharmacol. 2008;62(5): 875-880.
87. Ajani JA, Jiang Y, Faust J, et al. A multicenter phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric, or gastroesophageal junction adenocarcinoma. Invest New Drugs. 2006;24(4):353-357.
88. Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol. 1996;14(1):164-170.
89. Heath EI, Urba S, Marshall J, Piantadosi S, Forastiere AA. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs. 2002;20(1):95-99.
90. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15(6):955-959.
91. Anderson SE, O'Reilly EM, Kelsen D P, Ilson DH. Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esopha-geal cancer. Cancer Invest. 2003;21(4):512-516.
92. Burkart C, Bokemeyer C, Klump B, Pereira P, Teichmann R, Hartmann JT. A Phase II trial of weekly irinotecan in cisplatin- refractory esophageal cancer. Anticancer Res. 2007;27(4C):2845-2848.
93. Ford H, Marshall A, Wadsley J, et al. Cougar-02: A randomized phase Ill study of docetaxel versus active symptom control in advanced esophagogastric adenocarcinoma. J Clin Oncol. 2012;30.
94. Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory esophageal cancer. Br J Cancer. 2003;89(4):630-633.
95. Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol. 2009;20(7):1242-1248.
96. Shim HJ, Cho SH, Hwang JE, et al. Phase II study of docetaxel and cisplatin chemotherapy in 5-FU/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010;33(6):624-628.
97. Yoshioka T, Sakayori M, Kato S, et al. Dose escalation study of doc-etaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-FU, and radiation. Int J Clin Oncol. 2006;11(6):454-460.
98. Nakajima Y, Suzuki T, Haruki S, et al. A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. Hepatogastroenterology. 2008;55(86-87): 1631-1635.
99. Jin J, Xu X, Wang F, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol. 2009;4(8):1017-1021.
100. Osaka Y, Takagi Y, Hoshino S, Tachibana S, Tsuchida A, Aoki T. Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting. Dis Esophagus. 2006; 19(6):473-476.
101. Tanaka T, Fujita H, Sueyoshi S, et al. Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience. Chemotherapy. 2007;53:449-453.
102. Minamide J, Aoyama N, Takada K, Oota Y. Evaluation of docetaxel, CDDP, and 5-FU combined therapy as second-line chemotherapy for esophagus cancer. Gan To Kagaku Ryoho. 2007;34(1):49-52. Japanese [with English abstract].
103. Park BB, Im YH, Hwang IG, et al. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs. 2008;26(4):387-392.
104. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22(6):1367-1373.
105. Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010; 5(9):1472-1476.
106. Schoennemann KR, Bjerregaard JK, Hansen T P, et al. Biweekly cetuximab and irinotecan as second-line therapy in patients with gastroesophageal cancer previously treated with platinum. Gastric Cancer. 2011;14(3):219-225.
107. Ilson DH, Kelsen D, Shah M, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117(7):1409-1414.
108. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;24(30):4922-4927.
109. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of geftinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006;24(10): 1612-1619.
110. Ferry DR, Anderson M, Beddard K, et al. A phase II study of geftinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res. 2007;13(19):5869-5875.
111. Fuchs CS, Tomasek J, Cho JY, et al. REGARD: A phase Ill, randomized, double-blind ed trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on frst-line platinum- and/or fuoropyrimidine-containing combination therapy. J Clin Oncol. 2012;30.
112. Law S, Wong J. Current management of esophageal cancer. J Gastrointest Surg. 2005;9(2):291-310.